[Lovastatin efficacy and tolerance in primary hypercholesterolemia. The German Lovastatin Study Group].
In the course of an open multicentre clinical trial 786 patients (512 men, 274 women; mean age 52.4 +/- 11 years) with primary hypercholesterolaemia (total cholesterol 328 +/- 72 mg/dl, triglycerides 174 +/- 87 mg/dl, LDL cholesterol 246 +/- 73 mg/dl, and HDL cholesterol 50 +/- 18 mg/dl) received 20-80 mg lovastatin daily for 12 weeks, after a four-week placebo period. On this regimen the concentration of total cholesterol fell by 27% to 238 +/- 52 mg/dl (P less than 0.001) of triglycerides by 13% to 140 +/- 69 mg/dl (P less than 0.001), that of LDL cholesterol by 36% to 157 +/- 53 mg/dl (P less than 0.001). But HDL cholesterol rose by an average of 12% to 54 +/- 17 mg/dl (P less than 0.001). Lovastatin was tolerated very well by 79% of patients, well by 19%, and poorly by 2%. Mild undesirable side effects of the drug (in particular meteorism, constipation, diarrhoea and nausea) were reported by fewer than 10% of patients. These data indicate that lovastatin is effective and well tolerated also when broadly applied in clinical practice.
Thiery
J
J
Institut für Klinische Chemie, Klinikum Grosshadern, Universität München.
Basten
A
A
Sommerburg
C
C
Seidel
D
D
D000328:Adult; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013607:Tablets
D008055:Lipids; D008074:Lipoproteins; D013607:Tablets; D008148:Lovastatin
Wirksamkeit und Verträglichkeit von Lovastatin bei primärer Hypercholesterinämie. Die deutsche Lovastatin-Studiengruppe.